(AOF) – Biosynex lost 4.87% to 8.20 euros after publishing sharply falling annual revenues. 2023 turnover fell 53% to 93.1 million euros. This decline in the rapid test specialist must, however, be analyzed by distinguishing between activity linked to Covid-19 (-92%) and that in relation to other product ranges (+48%). For 2024, the group anticipates the return of an overall activity in progress with the growth of the two professions of family health and diagnostics.
The 2023 turnover of Covid-19 products recorded a decrease of 130 million euros in one year, which is in addition to a previous decrease of more than 200 million euros for the previous financial year. On the other hand, Biosynex continued its growth momentum in 2023 in its strategic target segments. Turnover excluding Covid-19 stood at 82.2 million euros, an increase of 48% compared to the previous financial year.
In accordance with its strategy aimed at being a player in personalized medicine, Biosynex has focused its development in 2023 on two key segments: monitoring of biotherapies and point of care.
The company also strengthened its leading position in this market in 2023 with the successful takeover bid for Theradiag. The contribution of acquisitions to 2023 sales of 17.6 million euros, and 46.3 million by broadening the focus to acquisitions made over the past 2 years. The green light from the FDA for the marketing of ProciseDx biotherapy monitoring tests also contributes to this strengthening.
“With the weight of Covid-19 products becoming very low, an expected increase in the contribution of the latest acquisitions and numerous commercial synergies both in France and abroad”, Biosynex “displays its confidence in its ability to deliver a sustainable growth trajectory.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
